INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales

Core Insights - Incyte Corporation reported fourth-quarter 2025 adjusted earnings of $1.80 per share, missing the Zacks Consensus Estimate of $1.94 due to higher operating expenses [1][9] - Total revenues for the fourth quarter reached $1.51 billion, reflecting a 28% year-over-year growth, driven by strong performance of Jakafi and Opzelura, and exceeding the Zacks Consensus Estimate of $1.35 billion [2][9] Revenue Breakdown - Jakafi sales amounted to $828.2 million, a 7% increase from the previous year, driven by an 11% rise in paid demand, surpassing the Zacks Consensus Estimate of $800 million [3][9] - Opzelura cream generated $207.3 million in sales, up 28% year over year, exceeding the Zacks Consensus Estimate of $195.9 million due to increased patient demand [4][9] - Newly approved Zynyz generated $31.7 million in sales, significantly up from the previous year and beating the Zacks Consensus Estimate of $21.7 million [5] - Iclusig sales were $34.2 million, a 25% year-over-year increase, surpassing the Zacks Consensus Estimate of $30.7 million [5] - Pemazyre sales reached $23.4 million, reflecting a 1% year-over-year increase, also exceeding the Zacks Consensus Estimate of $22.9 million [5] - Minjuvi's revenues totaled $41.9 million, up 28% year over year, slightly beating the Zacks Consensus Estimate of $41.2 million [6] New Product Approvals - Incyte and Syndax Pharmaceuticals received FDA approval for axatilimab-csfr, branded as Niktimvo, for GVHD treatment, generating $56 million in sales in Q4 2025, a 22% sequential increase [7] Financial Performance - Adjusted R&D expenses were $575.2 million, up 37% year over year, primarily due to investments in late-stage development assets [13] - Adjusted SG&A expenses were $365.3 million, up 22% from the prior year, driven by costs associated with U.S. oncology product launches [13] - As of December 31, 2025, Incyte's cash, cash equivalents, and marketable securities totaled $3.6 billion, up from $2.9 billion as of September 30, 2025 [15] Full-Year Results and Guidance - For 2025, Incyte generated revenues of $5.14 billion, a 21% year-over-year growth, beating the Zacks Consensus Estimate of $4.97 billion [16] - The company expects Jakafi revenues in the range of $3.22-$3.27 billion for 2026, with Opzelura net product revenues projected between $750-$790 million [17]